Search

In a sparse year for listings, the $10.2 billion float of Talabat, a food delivery company, on Dubai's exchange is set to become this year's biggest tech initial public offering. [ABSTRACT FROM AUTHOR]

Tempus AI's IPO and Insightec, BillionToOne funding rounds bode well for the medtech sector, according to PitchBook's Q2 report. [ABSTRACT FROM AUTHOR]

The 30-hospital for-profit health system landed at 12 million shares at $16 each, well below last week's plan for 14.3 million shares between $20 and $22. [ABSTRACT FROM AUTHOR]

Occupational health services provider Concentra aims to raise as much as $585 million in an initial public offering. [ABSTRACT FROM AUTHOR]

The 30-hospital for-profit health system plans to offer 14.3 million shares priced between $20 and $22 apiece. [ABSTRACT FROM AUTHOR]

Tempus AI raised $410.7 million via its IPO at an implied valuation of $6.1 billion. [ABSTRACT FROM AUTHOR]

Waystar's stock opened at $21, slightly below the IPO price. The company's shares slide more than 3% in their Nasdaq debut. [ABSTRACT FROM AUTHOR]

Rapport Therapeutics is talking up a $122 million IPO, the first in a return to public market interest since an earlier rush this year. [ABSTRACT FROM AUTHOR]

Healthcare payment software maker Waystar is looking to raise about $1.04 billion in an initial public offering, potentially marking the biggest IPO this year. [ABSTRACT FROM AUTHOR]

This week on "The Top Line," we explore the European biotech investment landscape. [ABSTRACT FROM AUTHOR]

Kyverna and Metagenomi are the two remaining biotechs to close IPOs in 2024's first tranche. [ABSTRACT FROM AUTHOR]

With the IPO window open, Metagenomi is the latest biotech to set out expectations for going public—even if they are more modest than its peers. [ABSTRACT FROM AUTHOR]

Alto Neuroscience and Fractyl Health are each set to rake in over $100 million from their respective IPOs this morning. [ABSTRACT FROM AUTHOR]

Kyverna plans to use $150 million of its anticipated IPO funding to push lead candidate KYV-101 through a broad suite of trials. [ABSTRACT FROM AUTHOR]

The home healthcare services provider plans to raise approximately $960 million in an IPO that would value the company at about $3 billion. [ABSTRACT FROM AUTHOR]

Kindbody is on track to reach nearly $300 million in revenue and to be cash flow positive this year, founder Gina Bartasi said. [ABSTRACT FROM AUTHOR]

The home and community-based healthcare services provider filed plans to go public with the SEC on Tuesday. [ABSTRACT FROM AUTHOR]

While the IPO markets are unlikely to unfreeze next year, according to Antoine Papiernik, the "silver lining" is Big Pharma's appetite for M&A. [ABSTRACT FROM AUTHOR]

Ron Baron, who reportedly owns a $1.7 billion stake in SpaceX, also expects the company to be worth $250 billion to $300 billion by that time. [ABSTRACT FROM AUTHOR]

Lexeo has disclosed plans to join the ranks of biotechs raking in nine figures from their IPO, despite downsizing its ambitions in recent days. [ABSTRACT FROM AUTHOR]

If it wasn't enough for Cargo to raise $200 million and recruit a C-suite of biopharma veterans this year, the CAR-T-focused company is eying an IPO. [ABSTRACT FROM AUTHOR]

Healthcare payment software maker Waystar filed for an initial public offering and reported growing revenue in 2022. [ABSTRACT FROM AUTHOR]

Lexeo Therapeutics and Abivax are headed to Wall Street, filing IPOs late Friday while others wait and see. [ABSTRACT FROM AUTHOR]

Instacart was the second IPO this month, and another is expected to occur tomorrow. [ABSTRACT FROM AUTHOR]

RayzeBio overshot its own IPO expectations by raising $311 million, while Neumora was squarely on target with a $250 million offering. [ABSTRACT FROM AUTHOR]

Neumora and RayzeBio are both casting a line into the market, with each seeking to raise more than $200 million in initial public offerings this fall. [ABSTRACT FROM AUTHOR]

Beleaguered digital health company Babylon Health finalized plans to go private and will combine with digital therapeutics company MindMaze. [ABSTRACT FROM AUTHOR]

The present article discusses the Action Plan on Building a Capital Markets Union approved by the EU Commission from the perspective of promoting corporate financing by means of securities offerings (for sale of securities) in EU primary markets. In this context, legal reforms provided under the Prospectus Regulation Proposal are under analysis to decrease regulatory entry barriers; especially, regarding its potential impact on divestment strategies implemented by venture capital/private equity investors. [ABSTRACT FROM AUTHOR]

Bright Health's financial woes continue, and the company is now at risk of being pulled from the New York Stock Exchange. [ABSTRACT FROM AUTHOR]

An Oscar Health shareholder has hit the insurer with a class-action suit, alleging that it obfuscated COVID's impact on its finances ahead of its IPO. [ABSTRACT FROM AUTHOR]

2021 saw a rush of biotechs heading for the public markets, including companies seeking an initial public offering before ever producing a shred of clinical evidence. [ABSTRACT FROM AUTHOR]

A year after pulling back its IPO in the face of the pandemic, construction-focused cloud software maker Procore and CEO Tooey Courtemanche saw shares jump in their debut on the New York Stock Exchange. [ABSTRACT FROM AUTHOR]

With $80 billion Snowflake, the biggest software IPO ever, he's rewritten the playbook. [ABSTRACT FROM AUTHOR]

Dustin Moskovitz's software business Asana's successful direct listing on Wednesday represents a challenge to the traditional IPO. [ABSTRACT FROM AUTHOR]

Some point to Snowflake's IPO as the latest and biggest example of lost billions in an IPO pop. CEO Frank Slootman strongly disputes the argument. [ABSTRACT FROM AUTHOR]

Cloud database company Snowflake opened trading at more than double its list price, making CEO Frank Slootman, ex-CEO Bob Muglia and cofounder Benoit Dageville billionaires. [ABSTRACT FROM AUTHOR]

The news comes about a year after Blackstone Group bought a majority stake in Bumble for $3 billion. [ABSTRACT FROM AUTHOR]

Special purpose acquisition companies have become all the rage on Wall Street this year. [ABSTRACT FROM AUTHOR]

"There's no set date and more flexibility," experts say. [ABSTRACT FROM AUTHOR]

The insurtech's stock more than doubled in its public market debut. [ABSTRACT FROM AUTHOR]

Casper's low valuation confirms that it's no longer a unicorn—far from it, actually. [ABSTRACT FROM AUTHOR]

David Solomon defended the bank's work on WeWork's failed IPO, even after it cost Goldman $80 million. [ABSTRACT FROM AUTHOR]